Gilead partners with the Global Fund to support Yeztugo access strategy on heels of FDA nod

Gilead Sciences is pushing full speed ahead with its strategy to ensure global access to its long-acting HIV pre-exposure prophylaxis (PrEP) drug Yeztugo (lenacapavir), tapping the Global Fund to F | The agreement is meant to help bolster affordable supply of the long-acting PrEP drug while Gilead’s voluntary licensing program with generics makers gets up and running.Read More